Across
- 2. Our latest data published in June 2025
- 3. Our 1st line patient profile actors name
- 4. Licensed for eligible MF patients with moderate to severe
- 6. Considered as gold standard treatment of MF for the last decade in the UK
- 8. Trial used to outline secondline patients in Omjjara treatment
- 9. The length of time from a starting point (like diagnosis or treatment start) until death from any cause
Down
- 1. Our 2nd line patient profile actors name
- 4. Inhibtion of the following protein leads to more readliy available iron and rbc production
- 5. The condition Omjjara is licensed to treat
- 7. Trial used to outline first line patients in Omjjara treatment